SecBot SecBot
8-K ·Filed Aug 25, 2026

RGNX

REGENXBIO Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed2mo ago SEC0001193125-26-365287
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for upcoming late-stage pipeline catalysts (RGX-202 for Duchenne, ABBV-RGX-314 for wet AMD/diabetic retinopathy) which are the primary value drivers. The board refresh is routine and does not change the near-term outlook.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

RGNX drug pipeline →

surabgene lomparvovec

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
Next catalyst
None dated

What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$9.38
T+0 close · Aug 25, 2026 · via day close
Latest settled
−22.81%
T+20 · $7.24 · next T+60 in 2d
Vs SPY
−23.04%
α at T+20
Latest observation
+9.60%
T+55 · FF3 residual α
  1. T+0 · Aug 26 $9.38entry
  2. T+1 · 3mo ago −0.11%α −0.76% · $9.37
  3. T+5 · 3mo ago +2.35%α +2.47% · $9.60
  4. T+20 · 8w ago −22.81%α −23.04% · $7.24
  5. T+57 · todayOpen
  6. T+60 · in 2d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

REGENXBIO appointed Greg Ciongoli as a Class II director and accepted the resignations of Jean Bennett and Jerry Karabelas, effective August 25, 2026. The board was reduced to nine members. This is a routine board refresh with no material financial impact, though Ciongoli's capital-markets background is notable as the company approaches late-stage pipeline catalysts.

Key Facts

  • Greg Ciongoli elected as Class II director effective August 25, 2026.
  • Ciongoli received an initial equity award with aggregate grant date fair value of $550,000 (75% stock option, 25% RSUs).
  • Option exercise price: $8.91 per share.
  • Jean Bennett, M.D., Ph.D. and A.N. Jerry Karabelas, Ph.D. resigned from the board effective August 25, 2026.
  • Board size reduced to nine directors.
  • Ciongoli will serve on the Audit Committee and Nominating and Corporate Governance Committee.
  • Ciongoli is Founder and Managing Partner of Adiumentum Capital Management.

Financial Impact

Initial equity award of $550,000 to new director; annual retainers of $45,000 (board), $10,000 (Audit Committee), $5,000 (Nominating and Corporate Governance Committee).

Risk Factors

  • No material financial or operational risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-365287
Document: 0001193125-26-365287-index.html0001193125-26-365287
Document: 0001193125-26-365287.txt0001193125-26-365287

Track record

15 reports on RGNX

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
  2. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
  3. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
  4. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
  5. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
  6. Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
  7. Aug 25, 202611w ago 8-K Neutral 3/10 Viewing Entry $9.38 Now $7.32 −21.96% settles Nov 19
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
  9. Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
  10. Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 25, 2026